Regeneron Pharma (NASDAQ: REGN) reported second quarter EPS of $12.89, $4.39 better than the analyst estimate of $8.50. Revenue for the quarter came in at $3.68B versus the consensus estimate of $3.29B.
Regeneron Pharma’s stock price closed at $545.46. It is down -9.93% in the last 3 months and down -49.60% in the last 12 months.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.